|Specificity:||The antibody LT27 reacts with CD27 (T14), a 50-55 kDa type I transmembrane glycoprotein (member of the TNF-receptor superfamily) expressed on medullary thymocytes, peripheral T lymphocytes, some B lymphocytes and NK cells.
HLDA V; WS Code T T-CD27.01
|Immunogen:||Human peripheral blood lymphocytes|
|Preparation:||The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (2 ml) is sufficient for 100 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD27 is a transmembrane 55 kDa protein of the nerve growth factor-receptor family, expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells. Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid. This sCD27 is an important prognostic marker of acute and chronic B cell malignancies. RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70.|
*van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA: Expression and release of CD27 in human B-cell malignancies. Blood. 1993 Dec 1;82(11):3430-6.
*Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, Matera R, Gandolfo GM, Musto P. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica. 1998 May;83(5):398-402.
*Kara IO, Sahin B, Gunesacar R: Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther. 2007 Jan-Feb;24(1):29-40.
*Yun LW, Decarlo AA, Hunter N: Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis. Clin Exp Immunol. 2007 Nov;150(2):217-29.
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr;15(4):1246-61.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic